Article thumbnail

Upregulation of MiR-155 in Nasopharyngeal Carcinoma is Partly Driven by LMP1 and LMP2A and Downregulates a Negative Prognostic Marker JMJD1A

By Zi-Ming Du, Li-Fu Hu, Hai-Yun Wang, Li-Xu Yan, Yi-Xin Zeng, Jian-Yong Shao and Ingemar Ernberg

Abstract

The role of microRNA-155 (miR-155) has been associated with oncogenesis of several human tumors. However the expression pattern of miR-155 has not been investigated in nasopharyngeal carcinoma (NPC). The present study was to assess miR-155 expression pattern and its possible function in NPC, to identify its targets and evaluate their clinical applications in NPC. MiR-155 was found to be upregulated in two Epstein-Barr virus (EBV) negative NPC derived cell lines CNE1 and TW03, as well as in NPC clinical samples by quantitative Real-time PCR and in situ hybridization detection. EBV encoded LMP1 and LMP2A could further enhance the expression of miR-155 in NPC CNE1 and TW03 cells. JMJD1A and BACH1 were identified as putative targets of miR-155 in a bioinformatics screen. Overexpression of miR-155 downregulated a luciferase transcript fused to the 3′UTR of JMJD1A and BACH1. MiR-155 mimic could downregulate the expression of JMJD1A and BACH1, while miR-155 inhibitor could upregulate JMJD1A expression in NPC cell lines. Moreover, downregulation of JMJD1A was significantly correlated with N stage in TNM classification (p = 0.023), a lower five-year survival rate (p = 0.021), and a lower five-year disease-free survival rate (p = 0.049) of NPC patients. Taken together, up-regulation of miR-155 in NPC is partly driven by LMP1 and LMP2A, and results in downregulation of JMJD1A, which is associated with N stage and poor prognosis of NPC patients. The potential of miR-155 and JMJD1A as therapeutic targets in NPC should be further investigated

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3082546
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). A custom microarray platform for analysis of microRNA gene expression.
  2. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets.
  3. (1994). A new staging system for nasopharyngeal carcinoma in China.
  4. (2006). A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA).
  5. (2008). Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth.
  6. (2010). Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.
  7. (2009). Aberrant overexpression of microRNAs activate AKT signaling via downregulation of tumor suppressors in natural killer-cell lymphoma/leukemia.
  8. (1998). Aetiology of nasopharyngeal carcinoma. A review.
  9. (1999). Ahmad A
  10. (2003). Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase1 gene in human cells.
  11. (2005). BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.
  12. (2003). Cancer of the nasopharynx.
  13. (1993). Characterization of seven newly established nasopharyngeal carcinoma cell lines.
  14. (2005). Combinatorial microRNA target predictions.
  15. (2004). Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
  16. (2010). Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas.
  17. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
  18. (2008). EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.
  19. (2010). Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival.
  20. (2005). Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase (hTERT) in epithelial cell lines.
  21. (2008). Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway.
  22. (2008). Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence.
  23. (2007). Epstein-Barr virusencoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a.
  24. (2007). Ernberg I
  25. (2002). Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes.
  26. (2009). Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microrNA-199.
  27. (1988). Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.
  28. (2004). Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma.
  29. (2004). Human MicroRNA targets.
  30. (2007). Huttenhofer A
  31. (2008). Hypoxia upregulates the histone demethylase JMJD1A via HIF-1.
  32. (2010). Identification of a microRNA panel for clear-cell kidney cancer.
  33. (1991). Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma.
  34. (2007). Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells.
  35. (2007). Kaposi’s sarcoma-associated herpesvirus encodes an ortholog of miR-155.
  36. (2000). Mammalian oxygen sensing, signalling and gene regulation.
  37. (2009). MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma.
  38. (2008). MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility.
  39. (2009). MicroRNA miR-155 is a biomarker of early pancreatic neoplasia.
  40. (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
  41. (2006). microRNA target predictions in animals.
  42. (2003). MicroRNA targets in Drosophila.
  43. (2010). MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene.
  44. (2008). MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways.
  45. (2008). MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA.
  46. (2010). MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer.
  47. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function.
  48. (2009). miR-155 gene: a typical multifunctional microRNA.
  49. (2007). Modulation of miR-155 and miR-125b levels following lipopolysaccharide/ TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock.
  50. (2011). MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia.
  51. (2011). NFkappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.
  52. (2009). Onco-miR155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas.
  53. (2003). Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg
  54. (2011). Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization.
  55. (2010). Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth.
  56. (1992). Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during
  57. (2009). Role of microRNA-155 at early stages of hepatocarcinogenesis induced by cholinedeficient and amino acid-defined diet in C57BL/6 mice.
  58. (2010). Signatures of microRNAs and selected microRNA target genes in human melanoma.
  59. (2008). Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder.
  60. (2010). Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis.
  61. (2005). The role of microRNA genes in papillary thyroid carcinoma.
  62. (2007). Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its
  63. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.